GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ginkgo Bioworks Holdings Inc (NYSE:DNA) » Definitions » Cash Conversion Cycle

Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Cash Conversion Cycle : -31.36 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Ginkgo Bioworks Holdings Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Ginkgo Bioworks Holdings's Days Sales Outstanding for the three months ended in Dec. 2023 was 106.39.
Ginkgo Bioworks Holdings's Days Inventory for the three months ended in Dec. 2023 was 0.8.
Ginkgo Bioworks Holdings's Days Payable for the three months ended in Dec. 2023 was 138.55.
Therefore, Ginkgo Bioworks Holdings's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was -31.36.


Ginkgo Bioworks Holdings Cash Conversion Cycle Historical Data

The historical data trend for Ginkgo Bioworks Holdings's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ginkgo Bioworks Holdings Cash Conversion Cycle Chart

Ginkgo Bioworks Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
- -156.56 69.42 73.76 20.92

Ginkgo Bioworks Holdings Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.58 43.30 5.63 -48.95 -31.36

Competitive Comparison of Ginkgo Bioworks Holdings's Cash Conversion Cycle

For the Biotechnology subindustry, Ginkgo Bioworks Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ginkgo Bioworks Holdings's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Ginkgo Bioworks Holdings's Cash Conversion Cycle falls into.



Ginkgo Bioworks Holdings Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Ginkgo Bioworks Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=72.84+14.9-66.82
=20.92

Ginkgo Bioworks Holdings's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=106.39+0.8-138.55
=-31.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ginkgo Bioworks Holdings  (NYSE:DNA) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Ginkgo Bioworks Holdings Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Ginkgo Bioworks Holdings's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Business Description

Traded in Other Exchanges
Address
27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Foundry and Biosecurity. The Biosecurity segment generates the majority of revenue.
Executives
Jason R Kelly director, officer: CEO & Founder 667 MADISON AVENUE, C/O CORVEX MANAGEMENT LP, NEW YORK NY 10065
Mark E. Dmytruk officer: Chief Financial Officer C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Barry Canton 10 percent owner C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Reshma P. Shetty director, 10 percent owner, officer: President, COO & Founder C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Christian O Henry director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Harry Sloan director, officer: CEO, Chairman 1450 2ND STREET, SUITE 247, SANTA MONICA CA 90401
Shyam Sankar director C/O PALANTIR TECHNOLOGIES INC., 1200 17TH STREET, FLOOR 15, DENVER CO 80202
Steven P. Coen officer: Chief Accounting Officer C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marie E. Fallon officer: Chief Accounting Officer C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marijn E Dekkers director GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Kathy Hopinkah Hannan director ANNALY CAPITAL MANAGEMENT, INC., 1211 AVE. OF THE AMERICAS, NEW YORK NY 10036
David C. Ott 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830